Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Cognitive and Depressive Symptoms in Adults with Common Variable Immunodeficiency (CVID)
Autoimmune Neurology
P16 - Poster Session 16 (5:30 PM-6:30 PM)
15-003
Assess cognitive and depressive symptoms in adults diagnosed with common variable immunodeficiency (CVID). 
CVID is defined by low levels of IgG, poor vaccine response, and onset after age 2-4 years with exclusion of other causes of immunodeficiency. Patients are at risk of recurrent infections, autoimmunity, and malignancy.
This is a prospective, epidemiological study assessing adults diagnosed with CVID at the University of Utah for depression and cognitive complaints. We used the Neuro QoL Depression and Cognitive Function Questionnaires as validated instruments to ascertain the degree of depression and cognitive dysfunction. A standard student t-test was used to compare the mean scores of CVID patients to both the general population (GP) and disease control (multiple sclerosis [MS]) population. 
Of 154 patients contacted, 71 completed the survey (46% response rate, mean age 50.4 years, 76.9% female respondents). Depression was reported by 64.8% of CVID patients compared to 16.2% of GP and 36%-54% in MS patients. The mean depression Neuro-QoL t-score is 50.6 (SD +/- 5.6 p value <.0001) when compared to both those with no health conditions and those with 1-2 reported conditions. Cognitive complaints were reported by 73.9% of CVID patients, compared to 6.7%-14.8% in the GP and 40-70% in MS patients. CVID patients have a mean cognitive Neuro-QoL t-score of 45.1 (SD +/-11.2, p. value <.0001) when compared to both those with no health conditions and those with 1-2 reported conditions. 
Depression and cognitive symptom rates are not only significantly higher in CVID patients when compared to GP and MS patients, but are also often overlooked and under-evaluated in the treatment of CVID patients. Given the bidirectionality between depression and cognitive complaints, addressing both mood and memory complaints should be a treatment priority in CVID patients, in addition to the standard immune globulin replacement treatment.
Authors/Disclosures
Bruno I. De Almeida (Unversity of Utah)
PRESENTER 		No disclosure on file
Lawanda Esquibel No disclosure on file
Leah Millsap, PhD (University of Utah) Dr. Millsap has nothing to disclose.
Julia Klein, NP (University of Utah School of Medicine) An immediate family member of Ms. Klein has received personal compensation for serving as an employee of Amgen. An immediate family member of Ms. Klein has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen.
Jonathan R. Galli, MD (University of Utah) Dr. Galli has nothing to disclose.
Melissa M. Cortez, DO (University of Utah Neurology) The institution of Dr. Cortez has received research support from NIH NINDS. The institution of Dr. Cortez has received research support from Dysautonomia International. Dr. Cortez has received personal compensation in the range of $500-$4,999 for serving as a Content Expert, Reviewer, DSMB with NIH RECOVER project.
M. M. Paz Soldan, MD, PhD (Mayo Clinic) Dr. Paz Soldan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. The institution of Dr. Paz Soldan has received research support from National Institutes of Health. The institution of Dr. Paz Soldan has received research support from National Multiple Sclerosis Society. The institution of Dr. Paz Soldan has received research support from Western Institute for Biomedical Research. The institution of Dr. Paz Soldan has received research support from Biogen. The institution of Dr. Paz Soldan has received research support from Novartis. The institution of Dr. Paz Soldan has received research support from Clene Nanomedicine.
No disclosure on file
John E. Greenlee, MD, FÂ鶹´«Ã½Ó³»­ (University of Utah) Dr. Greenlee has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Medlink. Dr. Greenlee has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Zeigler Cohen Roche. Dr. Greenlee has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Sommers Schwartz PC. Dr. Greenlee has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for St Francis Hospital. Dr. Greenlee has received publishing royalties from a publication relating to health care. Dr. Greenlee has received publishing royalties from a publication relating to health care.
John W. Rose, MD, FÂ鶹´«Ã½Ó³»­ (Imaging and Neurosciences Center) The institution of Dr. Rose has received research support from National Multiple Sclerosis Society. The institution of Dr. Rose has received research support from Guthy Jackson Charitable Foundation. The institution of Dr. Rose has received research support from NIH . The institution of Dr. Rose has received research support from VA. The institution of Dr. Rose has received research support from Biogen. The institution of Dr. Rose has received research support from Friends of MS. Dr. Rose has received intellectual property interests from a discovery or technology relating to health care.
Harry H. Hill, MD No disclosure on file
Ka-Ho Wong (U of U Neurology Clinic) The institution of Mr. Wong has received research support from The Sumaira Foundation . The institution of Mr. Wong has received research support from The Siegel Rare Neuroimmune Association.
Stacey Clardy, MD, PhD, FÂ鶹´«Ã½Ó³»­ (University of Utah) Dr. Clardy has received personal compensation for serving as an employee of Veterans Health Administration (VHA). Dr. Clardy has received personal compensation for serving as an employee of University of Utah Health. Dr. Clardy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca/Alexion. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen/Horizon. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arialys. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kyverna. Dr. Clardy has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology/Â鶹´«Ã½Ó³»­ Publications. The institution of Dr. Clardy has received research support from NIH/NINDS. The institution of Dr. Clardy has received research support from SRNA. The institution of Dr. Clardy has received research support from Alexion/AstraZeneca. The institution of Dr. Clardy has received research support from Kyverna. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving as a Â鶹´«Ã½Ó³»­ Summer Meeting CoDirector Travel and Lodging with Â鶹´«Ã½Ó³»­. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving as a Grand Rounds Travel/Lodging/Honoraria with U of Iowa, Miami, Stanford, Barrow, Advent Health Florida, Beaumont Health, CCF, Emory, Penn State Health, Mayo Clinic, Walter Reed.